SUMMARY OF PRODUCT CHARACTERISTICS

Similar documents
Summary of Product Characteristics

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. Equest Oral Gel, 18,92 mg/g, Oral Gel for Horses and Ponies

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

For the treatment and prevention of infections caused by:

[Version 8, 10/2012] SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCTS CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Summary of Product Characteristics

Health Products Regulatory Authority

SUMMARY of PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Ubroseal Dry Cow 2.6 g intramammary suspension for cattle

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Summary of Product Characteristics

Tablet. A light-brown to brown, meat flavoured, bone shaped tablet scored on both sides that can be divided into halves.

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Equimax Tabs Vet, 150 mg / 20 mg, Chewable tablet for Horses

Treatment of mixed infections by nematodes and cestodes of the following species:

Part II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Vetoquinol/DOLPAC Small dogs/european Renewal June 2011 SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

Summary of Product Characteristics

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Lincomycin (as Lincomycin hydrochloride) Neomycin (as Neomycin sulphate) Excipients Disodium edetate

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

PART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN

SUMMARY of PRODUCT CHARACTERISTICS (SPC)

SUMMARY OF PRODUCT CHARACTERISTICS

Irish Medicines Board

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

Irish Medicines Board

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER

LABELLING AND PACKAGE LEAFLET

SUMMARY OF THE PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Summary of Product Characteristics

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Active substance: Imidacloprid 40 mg/pipette (0.4 ml of a 10 % solution)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF THE PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

Error! Reference source not found. I. SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

Transcription:

SUMMARY OF PRODUCT CHARACTERISTICS Revised: March 2011 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Strongid - P Paste 43.90% w/w 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Pyrantel Embonate 43.90 %w/w For a full list of excipients see section 6.1 3. PHARMACEUTICAL FORM Oral paste. A smooth, pale yellow to buff paste for oral administration. 4. CLINICAL PARTICULARS 4.1 Target Species Horses, ponies, donkeys and foals over four weeks of age. 4.2 Indications for Use, Specifying the Target Species A broad spectrum anthelmintic for use in horses and donkeys for the control and treatment of adult infections of large and small strongyles, Oxyuris, Parascaris and Anoplocephala perfoliata. Effective against benzimidazole resistant strains of small strongyles. 4.3 Contraindications Not for use in horses with known hypersensitivity to the active ingredient. 4.4 Special warnings for each target species Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device.(if any) Page 1 of 5

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintics belonging to another pharmacological class and having a different mode of action should be used. Resistance to pyrantel has been reported in cyathostomes in horses (also widespread in the US and Canada). Therefore the use of this product should be based on a local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics. 4.5 Special precautions for use i. Special precautions for use in animals The same oral doser should only be used to dose two animals if they are both healthy and are either running together, or are on the same premises and in direct contact with each other. Only for direct oral administration. ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals Avoid contact with skin. Wash hands and any other parts of the body which come into contact with the product. 4.6 Adverse reactions (frequency and seriousness) None known 4.7 Use during pregnancy, lactation or lay The product is specifically recommended for use in mares which may be pregnant and/or lactating. No adverse effects have been found or reported in trials using higher than recommended dosages. 4.8 Interaction with other medicinal products and other forms of interaction None known. 4.9 Amounts to be administered and administration route Administration: Strongid-P Paste is recommended for direct oral administration in horses, ponies, donkeys and foals over four weeks of age. It is not necessary to withhold any feed prior to administration. The following method of administration is recommended: Page 2 of 5

1. Position the locking ring over the appropriate mark on the plunger. 2. Remove the cap from the nozzle. 3. The paste is best deposited on the upper surface of the tongue. Introduce the nozzle end of the oral doser at the corner of the mouth. Direct the oral doser backwards and depress the plunger to deposit the paste onto tongue. Providing the paste is given in this way it is unlikely that any rejection will occur. Raising the head by a hand under the chin sometimes helps with swallowing. Dosage: For the control and treatment of strongyles Oxyuris and Parascaris but excluding Anoplocephala (tapeworm). Strongid-P Paste should be used at a dose rate of 19 mg pyrantel embonate per kg bodyweight. Bodyweight range Dose contents of Dose of pyrantel embonate Up to 150kg ¼ oral doser 2.85g 151 300kg ½ oral doser 5.70g 301 450kg ¾ oral doser 8.55g 451 600kg Full oral doser 11.40g Note: Position locking ring over appropriate mark on plunger. Dosing Programmes: Strongyles. Oxyuris and Parascaris. Foals: one to eight months of age - dose every four weeks. Horses and donkeys: over eight months of age - routinely dose every six to eight weeks, but during the summer and autumn when horses and donkeys are at grass, dose every four to six weeks. Always dose three to four days before turning out after in-wintering. Suckler mares: It has been shown that reduction of strongyle challenge to the suckling foal at pasture can be achieved by using clean pasture (re-seeded, or not grazed the previously year by horses), dosing the mare three to four days before turning out and then at intervals of two to four weeks until the end of autumn. Ideally mares with foals should go out to clean pasture or, if this is not possible delay, turning them out until June. Dosage: For the control and treatment of tapeworms: Strongid-P Paste should be used at a dose rate of 38 mg pyrantel embonate per kg bodyweight, that is twice the dose rate for strongyles. Dosing programme Tapeworm: The need for re-treatment may vary, but if considered necessary should be carried out after an interval of six weeks. To ensure administration of a correct dose, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked. Page 3 of 5

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary The product has an extremely wide safety margin and overdosage should not produce any adverse reactions. 4.11 Withdrawal Period(s) Horse meat: zero days. 5. PHARMACOLOGICAL PROPERTIES Pyrantel embonate is a member of the tetrahydropyrimidine class of anthelmintic compounds. It possesses broad spectrum activity against the major gastro-intestinal helminths of animals and man. It is effective against the following gastro-intestinal helminths of foals, adult horses and donkeys. Large and small strongyles (including benzimidazole-resistant strains of small strongyles) Oxyuris equi Parascaris equorum Anoplocephala perfoliata Pyrantel acts as a potent agonist at acetylcholine (ACh) receptors on muscle cells of nematodes leading to neuromuscular block characteristic of depolarising agents. This results in a prolonged spastic paralysis of the worm and expulsion from the host. Pyrantel embonate is relatively insoluble and poorly absorbed from the gut. Its activity is confined to parasites dwelling within the gut lumen. The small amount of pyrantel absorbed into the circulation is rapidly metabolised and the drug metabolites have no toxic potential. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Polysorbate 80 Methyl Hydroxybenzoate Propyl Hydroxybenzoate Sorbitol Solution 70%w/w (non-crystallising) Sodium Alginate Water purified 6.2 Incompatibilities None known. 6.3 Shelf-life Shelf-life of the veterinary medicinal product as packaged for sale: 3 years. Shelf-life after first opening the immediate packaging: 2 months. Page 4 of 5

6.4 Special Precautions for Storage Protect from direct sunlight. Do not store above 25 C. Store in a tightly closed original container. 6.5 Nature and composition of immediate packaging Pack size: Container: Closure: Content: 26g Metering syringe with high density polyethylene barrel, plunger and locking ring. Low density polyethylene piston and endcap. Pale yellow to buff coloured oral paste. 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products, if appropriate Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER Elanco Animal Health Eli Lilly & Company Limited Lilly House Priestly Road Basingstoke Hampshire RG24 9NL 8. MARKETING AUTHORISATION NUMBER(S) Vm 00006/4130 9. DATE OF THE FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 23 rd May 2004 10. DATE OF REVISION OF THE TEXT March 2011 Page 5 of 5